<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion/References</th>
<th>Institution Vote</th>
</tr>
</thead>
</table>
| VTE-E, (1 of 3) and (2 of 3) Internal request to add new direct oral anticoagulants as options for treatment of venous thromboembolism | Based on discussion of subgroup analyses of cancer patients in randomized controlled trials (see references), panel consensus supported adding: 1. Apixaban and rivaroxaban as therapeutic anticoagulation options for acute management of venous thromboembolism in patients who refuse or have compelling reasons to avoid LMWH (category 2A). 2. Apixaban, dabigatran, edoxaban, and rivaroxaban were added as therapeutic anticoagulation options for chronic management of venous thromboembolism in patients who refuse or have compelling reasons to avoid LMWH (category 2A). References:  